Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer

被引:0
作者
Xiaodong Yu
Zhongbo Du
Pingyu Zhu
Bo Liao
机构
[1] Affiliated Hospital of North Sichuan Medical College,Department of Urology
来源
Pharmacological Reports | 2024年 / 76卷
关键词
Exosome; MicroRNA; Renal cell carcinoma; Diagnosis; Prognosis; Therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Renal cell carcinoma (RCC) arises from the tubular epithelial cells of the nephron. It has the highest mortality rate among urological cancers. There are no effective therapeutic approaches and no non-invasive biomarkers for diagnosis and follow‐up. Thus, suitable novel biomarkers and therapeutic targets are essential for improving RCC diagnosis/prognosis and treatment. Circulating exosomes such as exosomal microRNAs (Exo-miRs) provide non-invasive prognostic/diagnostic biomarkers and valuable therapeutic targets, as they can be easily isolated and quantified and show high sensitivity and specificity. Exosomes secreted by an RCC can exhibit alterations in the miRs’ profile that may reflect the cellular origin and (patho)physiological state, as a ‘‘signature’’ or ‘‘fingerprint’’ of the donor cell. It has been shown that the transportation of renal-specific miRs in exosomes can be rapidly detected and measured, holding great potential as biomarkers in RCC. The present review highlights the studies reporting tumor microenvironment-derived Exo-miRs with therapeutic potential as well as circulating Exo-miRs as potential diagnostic/prognostic biomarkers in patients with RCC.
引用
收藏
页码:273 / 286
页数:13
相关论文
共 760 条
[1]  
Cao W(2021)Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 Chin Med J 134 783-791
[2]  
Chen HD(2019)Renal cell carcinoma staging: pitfalls, challenges, and updates Histopathology 74 18-30
[3]  
Yu YW(2018)The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma Cell Rep 23 313-26 e5
[4]  
Li N(2019)Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† Ann Oncol 30 706-720
[5]  
Chen WQ(2016)Renal cancer The Lancet 387 894-906
[6]  
Williamson SR(2016)Medical treatment of renal cancer: new horizons Br J Cancer 115 505-516
[7]  
Taneja K(2016)Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study World J Urol 34 1081-1086
[8]  
Cheng L(2019)Serum exosomal miR-210 as a potential biomarker for clear cell renal cell carcinoma J Cell Biochem 120 1492-1502
[9]  
Ricketts CJ(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[10]  
De Cubas AA(2016)Follow-up after treatment for renal cell carcinoma: the evidence beyond the guidelines Eur Urol Focus 1 272-281